Takeda's orexin agonist Orzeyful has been approved in the US to treat narcolepsy type 1 (NT1) in adults, becoming the first ...

The CDC has permanent leadership in place for the first time since August 2025, after the US Senate confirmed the appointment ...

For an emerging biopharma company developing an innovative therapy for a rare condition, 2026 presents a dilemma that may ...

A Netherlands-based compounding pharmacy has been ordered to stop distributing a compounded nasal spray formulation of Novo Nordisk's GLP-1 agonist semaglutide in a test of the country's pharmacy ...

There is no substance to the rumours of a $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb, according to ...

There's a change at the helm of Johnson & Johnson's pharma division in the offing, as executive vice president Jennifer ...

Patients in England with ultra-rare kidney disease nephropathic cystinosis will soon be able to access a therapy that has ...

Sanofi is reported to be preparing a move to take control of US biotech Ocular Therapeutix, after an initial bid was rejected last year. That is according to French newspaper La Lettre, which said ...

For decades, direct-to-consumer (DTC) advertising has been a defining feature of the US healthcare system. Across the nation, ...

Henry Gosebruch, pictured here during his time at Neumora, is replacing Paul Stoffels as CEO of Galapagos. Just a few months after announcing a plan to separate its drug and cell therapy businesses ...

Taiho Pharmaceutical has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy (DMD) missed the mark in a phase 3 trial. The REACH-DMD study of pizuglanstat ...

Moderna has started first-in-human testing of its mRNA vaccine against Bundibugyo Ebola virus (BDBV), now causing the ...